VERA

Vera TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$100.00

+219.9% vs current

Most likely

Base case

60%

Probability

Target price

$75.00

+139.9% vs current

B-

Bear case

15%

Probability

Target price

$33.00

+5.6% vs current

AI sentiment snapshot

Latest data as of 2026-01-13

AI commentary

Investor sentiment is mixed: consensus averages near ~$75 but the distribution stretches to ~$100, reflecting binary outcomes and model variance [#SERP-5][#SERP-8]. Frequent target revisions and coverage updates drive volatile re‑pricing around data and corporate news [#SERP-1]. Recent competitive developments and positioning by retail/institutional investors keep the tone cautiously optimistic but highly event‑sensitive [#SERP-9][#SERP-6].

RankAlpha Sentiment AI - 2026-01-13

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-13catalystNext quarterly financial reportHigh impact

Quarterly results will update cash runway and program timelines; small‑cap biotechs commonly re‑rate on cash/runway and milestone commentary [#SERP-6].

2026-06-30eventAnalyst coverage / consensus price‑target updatesHigh impact

Major brokers and aggregators periodically revise 12‑month targets; consensus currently shows a wide low‑to‑high spread that can amplify moves on revisions [#SERP-1][#SERP-5].

2027-01-13catalystClinical/regulatory milestone or program advancementHigh impact

A successful late‑stage readout or regulatory filing could materially re‑rate valuation; timing is uncertain so a conservative one‑year horizon is used.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-13 • Updated nightlySource: Internal modelMethodology